Abstract
Although the suppression of sympathetic activity is an essential mission for the current heart failure treatment strategy, little is known about the relationship between the rotation speed setting and autonomic nervous activity during continuous-flow left ventricular assist device (LVAD) treatment. We evaluated 23 adult patients with sinus rhythm (36 ± 13 years) who had received continuous-flow LVAD and been followed at our institute between March 2013 and August 2014. Heart rate variability measurement was executed along with hemodynamic study at 3 rotation speeds (low, middle, and high) at 5 weeks after LVAD implantation. Lower rotation speed was associated with higher ratio of low-frequency over high-frequency spectral level (LF/HF), representing enhanced sympathetic activation (p < 0.05 by repeated analyses of variance). Among hemodynamic parameters, cardiac index was exclusively associated with LFNU = LF/(LF + HF), representing relative sympathetic activity over parasympathetic one (p < 0.05). After 6 months LVAD support at middle rotation speed, 19 patients with higher LFNU eventually had higher plasma levels of B-type natriuretic peptide and achieved less LV reverse remodeling. A logistic regression analysis demonstrated that lower LFNU was significantly associated with improvement of LV reverse remodeling (p = 0.021, odds ratio 0.903) with a cut-off level of 55 % calculated by the ROC analysis (AUC 0.869). In conclusion, autonomic activity can vary in various rotation speeds. Patients with higher LFNU may better be controlled at higher rotation speed with the view point to suppress sympathetic activity and achieve LV reverse remodeling.
Similar content being viewed by others
Reference
Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand. 2003;177:391–8.
Metra M, Nodari S, D’Aloia A, Bontempi L, Boldi E, Cas LD. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J. 2000;139:511–21.
The Cardiac Insufficiency Bisoprolol Study II. (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.
George RS, Birks EJ, Cheetham A, Webb C, Smolenski RT, Khaghani A, Yacoub MH, Kelion A. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013;15:1035–43.
Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1–39.
Hori M, Nagai R, Izumi T, Matsuzaki M. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessel. 2014;29:238–47.
McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–64.
Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996;17:354–81.
Sawada Y, Ohtomo N, Tanaka Y, Tanaka G, Yamakoshi K, Terachi S, Shimamoto K, Nakagawa M, Satoh S, Kuroda S, Iimura O. New technique for time series analysis combining the maximum entropy method and non-linear least squares method: its value in heart rate variability analysis. Med Biol Eng Comput. 1997;35:318–22.
Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell’Orto S, Piccaluga E, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res. 1986;59:178–93.
Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981;213:220–2.
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–23.
Skorecki KL, Brenner BM. Body fluid homeostasis in man. A contemporary overview. Am J Med. 1981;70:77–88.
Frye RL, Braunwald E. Studies on Starling’s law of the heart. I. The circulatory response to acute hypervolemia and its modification by ganglionic blockade. J Clin Invest. 1960;39:1043–50.
Imamura T, Kinugawa K, Hatano M, Fu**o T, Inaba T, Maki H, Kinoshita O, Nawata K, Kyo S, Ono M, Komuro I. Low cardiac output stimulates vasopressin release in patients with stage d heart failure. Circ J. 2014;78:2259–67.
Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L–40L.
Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94:2285–96.
Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976;294:1165–70.
Imamura T, Kinugawa K, Kato N, Muraoka H, Fu**o T, Inaba T, Maki H, Kinoshita O, Hatano M, Kyo S, Ono M. Late-onset right ventricular failure in patients with preoperative small left ventricle after implantation of continuous flow left ventricular assist device. Circ J. 2014;78:625–33.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Imamura, T., Kinugawa, K., Nitta, D. et al. Lower rotation speed stimulates sympathetic activation during continuous-flow left ventricular assist device treatment. J Artif Organs 18, 20–26 (2015). https://doi.org/10.1007/s10047-014-0800-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-014-0800-2